Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line

Endocrinology

Volumn 139, Issue 10, 1998, Pages 4108-4114

  Brubaker, P L ^a,c   Schloos, J ^b   Drucker, D J ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b BEIERSDORF AG   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1; PROGLUCAGON; PROTEIN KINASE C;

ANIMAL CELL; ARTICLE; CELL LINE; DATA ANALYSIS; ENDOCRINE CELL; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTESTINE CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RNA TRANSCRIPTION;

EID: 0031765091     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.10.6228     Document Type: Article

References (47)

1. Kreymann B, Ghatei MA, Williams G, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
2. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
4. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
5. Ritzel R, Orskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720-725
6. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR 1995 Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421
7. Kolligs F, Fehmann H-C, Göke R, Göke B 1995 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19
8. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC 1996 Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530
9. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B 1996 Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553
10. Rachman J, Barrow BA, Levy JC, Turner RC 1997 Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211
11. Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR 1997 Glucagon-like peptide-1 (GLP-1): a trial of treatment in noninsulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536
12. Dupré J, Behme MT, Hramiak IM, McDonald TJ 1997 Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care 20:381-384
13. Ahrén B, Larsson H, Holst JJ 1997 Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478
14. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
15. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266
16. Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, Tateishi K, Sato I, Shima K 1997 Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46:745-749
17. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF 1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889
18. Drucker DJ, Brubaker PL 1989 Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci USA 86:3953-3957
19. Dhanvantari S, Seidah NG, Brubaker PL 1996 Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342-355
20. Huang THJ, Brubaker PL 1995 Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture. Endocrine 3:499-503
21. Rocca AS, Brubaker PL 1995 Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 136:5593-5599
22. Brubaker PL, Vranic M 1987 Fetal rat intestinal cells in monolayer culture: a new in vitro system to study the glucagon-related peptides. Endocrinology 120:1976-1985
23. Brubaker PL 1988 Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. Endocrinology 123:220-226
24. Brubaker PL 1991 Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128:3175-3182
25. Buchan AMJ, Barber DL, Gregor M, Soll AH 1987 Morphologic and physiologic studies of canine ileal enteroglucagon-containing cells in short-term culture. Gastroenterology 93:791-800
26. Barber DL, Gregor M, Soll AH 1987 Somatostatin and muscarinic inhibition of canine enteric endocrine cells: cellular mechanisms. Am J Physiol 253:G684-G689
27. i in enteric endocrine cells. Am J Physiol 261:G497-G503
28. Abello J, Ye F, Bosshard A, Bernard C, Cuber J-C, Chayvialle J-A 1994 Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. Endocrinology 134:2011-2017
29. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL 1994 Activation of proglucagon gene transcription by protein kinase A in a novel mouse enteroendocrine cell line. Mol Endocrinol 8:1646-1655
30. Vorum H, Broderson R, Kragh-Hansen U, Pederson AO 1992 Solubility of long-chain fatty acids in phosphate buffer at pH 7.4. Biochim Biophys Acta 1126:135-142
31. Campbell J, Martucci AD, Green GR 1964 Plasma albumin as an acceptor of free fatty acids. Biochem J 93:183-189
32. Ehrlich P, Tucker D, Asa SL, Brubaker PL, Drucker DJ 1994 Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. Am J Physiol 267:E662-E671
33. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Chem 162:156-159
34. Vadakekalam J, Rabaglia ME, Chen QH, Metz SA 1996 Role for GTP in glucose-induced phospholipase C activation in pancreatic islets. Am J Physiol 271:E85-E95
35. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI 1993 Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133:2861-2870
36. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA, O'Hara PJ, Foster D, Walker KM, Chen LHJ, McKernan PA, Kindsvogel W 1993 Expression cloning and signaling properties of the rat glucagon receptor. Science 259:1614-1616
37. Hermann-Rinke C, Vöge A, Hess M, Göke B 1995 Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 147:25-31
38. Dumoulin V, Dakka T, Plaisancie P, Chayvialle J-A, Cuber J-C 1995 Regulation of glucagon-like peptide-1-(7-36)amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 136:5182-5188
39. Roberge JN, Brubaker PL 1993 Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-240
40. Rocca AS, Brubaker PL 1998 Integration of neural and humoral elements in the control of glucagon-like peptide-1 secretion. Diabetes 47:110A (Abstract)
41. Balks HJ, Holst JJ, Von zur Mühlen A, Brabant G 1997 Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82:786-790
42. Sakurai H, Dobbs RE, Unger RH 1975 The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein and fat. Diabetologia 11:427-430
43. Bloom SR, Polak JM 1982 The hormonal pattern of intestinal adaptation: a major role for enteroglucagon. Scand J Gastroenterol [Suppl 74] 17:93-103
44. Viollet C, Prévost G, Maubert E, Faivre-Bauman A, Gardette R, Kordon C, Loudes C, Slama A, Epelbaum J 1995 Molecular pharmacology of somatostatin receptors. Fund Clin Pharmacol 9:107-113
45. Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S 1997 Molecular interactions between dynamin and G-protein βγ-subunits in neuroendocrine cells. Mol Cell Endocrinol 132:61-71
46. Dent P, Wang Y, Gu YZ, Wood SL, Reardon DB, Mangues R, Pellicer A, Schonbrunn A, Sturgill TW 1997 549 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. Cell Signal 9:539-549
47. Fürstenau U, Schwaninger M, Blume R, Kennerknecht I, Knepel W 1997 Characterization of a novel protein kinase C response element in the glucagon gene. Mol Cell Biol 17:1805-1816